Get the Stockscreener App
3.60
1.41%
0.05
Veru Inc stock is traded at $3.60, with a volume of 136.18K.
It is up +1.41% in the last 24 hours and down -36.84% over the past month.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
See More
Previous Close:
$3.55
Open:
$3.57
24h Volume:
136.18K
Relative Volume:
0.49
Market Cap:
$51.42M
Revenue:
$6.66M
Net Income/Loss:
$-25.52M
P/E Ratio:
-2.9752
EPS:
-1.21
Net Cash Flow:
$-28.98M
1W Performance:
+0.28%
1M Performance:
-36.84%
6M Performance:
-37.14%
1Y Performance:
-56.87%
1-Day Range:
$3.45
$3.6915
1-Week Range:
$3.20
$3.87
52-Week Range:
$2.64
$14.20
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
3.60 | 51.42M | 6.66M | -25.52M | -28.98M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Raymond James Financial Cuts Veru (NASDAQ:VERU) Price Target to $20.00 - MarketBeat
Veru (NASDAQ:VERU) Issues Quarterly Earnings Results - MarketBeat
Is Veru Inc.’s ROE strong enoughMarket Activity Summary & Momentum Based Trading Signals - thegnnews.com
Veru (NASDAQ:VERU) Sets New 52-Week LowWhat's Next? - MarketBeat
Price Floor Holding on Veru Inc. — Rebound PossibleJuly 2025 Recap & Technical Entry and Exit Alerts - newsyoung.net
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm - Yahoo Finance
Veru Inc. Charts Flash Early Recovery SignalsWeekly Volume Report & Low Risk High Win Rate Picks - newsyoung.net
Raymond James Keeps Their Buy Rating on Veru (VERU) - The Globe and Mail
Veru (STU:FMW0) Tariff Resilience Score : 5/10 (As of Aug. 14, 2025) - GuruFocus
Will Veru Inc. rebound enough to break evenQuarterly Profit Report & Fast Gain Swing Trade Alerts - Newser
Is Veru Inc. a strong growth stockMarket Volume Report & Short-Term Swing Trade Alerts - news-j.co.kr
What indicators show strength in Veru Inc.Options Play & Scalable Portfolio Growth Ideas - Newser
Why Veru Inc. stock attracts strong analyst attentionEarnings Beat & Safe Entry Zone Identification - Newser
Veru Inc. stock prediction for this weekMarket Risk Summary & Technical Buy Zone Confirmations - Newser
How sentiment analysis helps forecast Veru Inc.Trade Risk Summary & Weekly High Potential Stock Alerts - Newser
Top chart patterns to watch in Veru Inc.2025 Analyst Calls & Precise Buy Zone Tips - Newser
Is Veru Inc. meeting your algorithmic filter criteriaMarket Rally & Weekly Market Pulse Updates - Newser
Veru stock price target raised to $25 from $4 at Oppenheimer on GLP-1 muscle loss drug - Investing.com Australia
Raymond James Maintains Veru Inc(VERU.US) With Buy Rating, Raises Target Price to $20 - 富途牛牛
Anchoring Your Portfolio: Is VERU Stock a Safe Harbor? - investchronicle.com
VERU Stock: Analyst Maintains Outperform Rating, Lowers Price Ta - GuruFocus
Veru (FRA:FMW0) Tariff Resilience Score : 5/10 (As of Aug. 13, 2025) - GuruFocus
Veru stock price target lowered to $20 at Raymond James on obesity drug - Investing.com Nigeria
Statistical indicators supporting Veru Inc.’s strengthRecession Risk & Daily Profit Maximizing Tips - Newser
Veru Inc (VERU) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. Reports Positive Results and Progress - TipRanks
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewswire
Full technical analysis of Veru Inc. stockTrade Ideas Based on Fundamental Metrics - Newser
Is Veru Inc. stock forming a triangle patternStocks with Highest Alpha - thegnnews.com
Veru Q3 2025 Earnings Call Transcript - MarketBeat
Transcript : Veru Inc., Q3 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Veru's Q3 2025 Earnings Call: Unpacking Key Contradictions in Phase III Trial Costs and Enobosarm's Safety Profile - AInvest
VERU INC. SEC 10-Q Report - TradingView
Veru Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Veru Inc. Q3 2025 sees significant EPS miss - Investing.com
Veru Inc. (NASDAQ:VERU) Looks Inexpensive After Falling 40% But Perhaps Not Attractive Enough - 富途牛牛
Why Investors Shouldn't Be Surprised By Veru Inc.'s (NASDAQ:VERU) 40% Share Price Plunge - simplywall.st
Veru Implements 1-for-10 Reverse Stock Split - TipRanks
Veru Inc. Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - TradingView
Veru Inc. (VERU): A High-Risk, High-Reward Biotech Play with a Turnaround Story - AInvest
Evaluating Veru Inc. with trendline analysisFree Swing Setup With Technical Confirmation - Newser
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology - BioSpace
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology - Lelezard
Veru selects Laxxon’s SPID technology for modified-release enobosarm By Investing.com - Investing.com Nigeria
Veru selects Laxxon’s SPID technology for modified-release enobosarm - Investing.com
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology | FinancialContent - FinancialContent
Veru selects oral enobosarm formulation for development - The Pharma Letter
Veru Selects Novel Oral Formulation for Chronic Weight Loss Management Drug - MarketScreener
Veru selects modified release formulation for enobosarm weight drug - Investing.com
Veru selects modified release formulation for enobosarm weight drug By Investing.com - Investing.com UK
Veru Announces Selection of Novel Modified Release Oral - GlobeNewswire
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veru Inc Stock (VERU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rankowitz Michael L | Director |
Feb 19 '25 |
Buy |
0.58 |
54,721 |
31,919 |
250,000 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):